TABLE 3.
Cox proportional hazard models for progression‐free survival (PFS) in patients with non‐small‐cell lung cancer who received second‐line treatment
| Items | PFS (univariate analysis) | PFS (multivariate analysis) | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Male sex | 0.39 (0.16–0.96) | 0.04 | 0.43 (0.16–1.13) | 0.09 |
| Age, years, ≥75 | 2.00 (0.73–5.46) | 0.18 | ||
| Recurrence | 0.47 (0.11–2.04) | 0.32 | ||
| ECOG‐PS = 2 a | 7.58 (2.21–26.1) | 0.001 | 6.66 (1.77–25.0) | 0.005 |
| PD‐L1 ≥ 50% b | 1.12 (0.45–2.83) | 0.80 | ||
| Cachexia c | 1.16 (0.48–2.79) | 0.74 | ||
| DOC+RAM d | 0.56 (0.25–1.29) | 0.17 | 0.40 (0.16–0.98) | 0.045 |
| Smoker | 0.41 (0.13–1.24) | 0.12 | ||
| Liver metastasis | 2.65 (0.95–7.43) | 0.06 | ||
| Brain metastasis | 2.10 (0.69–6.45) | 0.19 | ||
| GPS ≥1 | 2.37 (0.97–5.77) | 0.06 | ||
| NLR ≥3 | 1.72 (0.72–4.07) | 0.22 | ||
| PNI ≥45.5 | 0.67 (0.26–1.71) | 0.40 | ||
Note: Univariate and multivariate analyses.
Abbreviations: CI, confidence interval; DOC, docetaxel; ECOG‐PS, Eastern Cooperative Oncology Group‐Performance Status; GPS, Glasgow Prognostic Score; NLR, neutrophil to lymphocyte ratio; PD‐L1, programmed death ligand 1; PNI, Prognostic Nutritional Index; RAM, ramucirumab.
ECOG‐PS = 2 vs. ECOG‐PS <2.
PD‐L1 TPS ≥50% vs. all others, except for unknown.
Weight loss amounting to >5% of body weight (BW) or body mass index <20 kg/m2 and weight loss amounting to >2% of BW with laboratory results exceeding reference values. Laboratory results exceeding reference values: C‐reactive protein > 0.5 mg/dl, serum Albumin < 3.2 g/dl, or Hemoglobin < 12 g/dl.
DOC + RAM versus single‐agent chemotherapy.